KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Operating Income (2020 - 2025)

Ginkgo Bioworks Holdings' Operating Income history spans 6 years, with the latest figure at -$70.8 million for Q4 2025.

  • For Q4 2025, Operating Income rose 31.71% year-over-year to -$70.8 million; the TTM value through Dec 2025 reached -$315.3 million, up 43.68%, while the annual FY2025 figure was -$315.3 million, 43.68% up from the prior year.
  • Operating Income reached -$70.8 million in Q4 2025 per DNA's latest filing, up from -$90.0 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$26.7 million in Q3 2021 to a low of -$1.7 billion in Q4 2021.
  • Average Operating Income over 5 years is -$288.8 million, with a median of -$178.1 million recorded in 2023.
  • Peak YoY movement for Operating Income: plummeted 2914.48% in 2021, then skyrocketed 86.3% in 2022.
  • A 5-year view of Operating Income shows it stood at -$1.7 billion in 2021, then surged by 86.3% to -$230.9 million in 2022, then grew by 22.85% to -$178.1 million in 2023, then surged by 41.83% to -$103.6 million in 2024, then surged by 31.71% to -$70.8 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Operating Income are -$70.8 million (Q4 2025), -$90.0 million (Q3 2025), and -$65.5 million (Q2 2025).